JP2001521924A - 鉄キレート化剤および酸化防止剤としてのオルト−ヒドロキシピリジノン誘導体 - Google Patents

鉄キレート化剤および酸化防止剤としてのオルト−ヒドロキシピリジノン誘導体

Info

Publication number
JP2001521924A
JP2001521924A JP2000518950A JP2000518950A JP2001521924A JP 2001521924 A JP2001521924 A JP 2001521924A JP 2000518950 A JP2000518950 A JP 2000518950A JP 2000518950 A JP2000518950 A JP 2000518950A JP 2001521924 A JP2001521924 A JP 2001521924A
Authority
JP
Japan
Prior art keywords
compound according
methyl
compound
alkyl
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000518950A
Other languages
English (en)
Japanese (ja)
Inventor
デイビッド ベッビントン，
ナット モンク，
スニール ガウール，
アラン パーマー，
リチャード ポーター，
クレイグ マルコム，
Original Assignee
バーナリス リサーチ リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バーナリス リサーチ リミテッド filed Critical バーナリス リサーチ リミテッド
Publication of JP2001521924A publication Critical patent/JP2001521924A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/69—Two or more oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
JP2000518950A 1997-10-31 1998-10-30 鉄キレート化剤および酸化防止剤としてのオルト−ヒドロキシピリジノン誘導体 Withdrawn JP2001521924A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9723078.3 1997-10-31
GBGB9723078.3A GB9723078D0 (en) 1997-10-31 1997-10-31 Chemical compounds
PCT/GB1998/003244 WO1999023075A1 (fr) 1997-10-31 1998-10-30 Derives d'ortho-hydroxypyridinone utilises comme agents chelateurs du fer et comme agents antioxydants

Publications (1)

Publication Number Publication Date
JP2001521924A true JP2001521924A (ja) 2001-11-13

Family

ID=10821419

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000518950A Withdrawn JP2001521924A (ja) 1997-10-31 1998-10-30 鉄キレート化剤および酸化防止剤としてのオルト−ヒドロキシピリジノン誘導体

Country Status (5)

Country Link
EP (1) EP1027335A1 (fr)
JP (1) JP2001521924A (fr)
AU (1) AU9638098A (fr)
GB (1) GB9723078D0 (fr)
WO (1) WO1999023075A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515599A (ja) * 2002-11-07 2006-06-01 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
JP2013521286A (ja) * 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション カテコールｏ−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用
JP2021518838A (ja) * 2018-04-26 2021-08-05 嘉▲興▼▲維▼眸生物科技有限公司Ｖｉｖａｖｉｓｉｏｎ Ｂｉｏｔｅｃｈ，Ｉｎｃ． 抗炎症化合物及びその製造並びに応用

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006108A1 (fr) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited Dérivés de 3-hydroxy-2(1H)-pyridinone ou 3-hydroxy-4(1H)-pyridinone et utilisation comme des capteurs des espèces d'oxygène réactifs (ROS)
EP1006112A1 (fr) * 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited Dérivés de 3-Hydroxy-2(1H)-pyridinone ou 3-hydroxy-4(1H)-pyridinone et utilisation en tant que capteurs d'espèces d'oxygène réaktifs (ROS)
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2469435A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
ATE373644T1 (de) 2002-02-05 2007-10-15 Bristol Myers Squibb Co N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
CN111170936B (zh) * 2020-01-19 2021-01-01 杭州泽德医药科技有限公司 3,4-二羟基-n-(1’-苄基-2’-羟乙基)-2-甲基吡啶氯化物及制备和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308055D0 (en) * 1983-03-24 1983-05-05 Hider R C Pharmaceutical compositions
US5336482A (en) * 1991-12-05 1994-08-09 The Du Pont Merck Pharmaceutical Company Technetium-99m complexes with N-substituted 3-hydroxy-4-pyridinones
US5624901A (en) * 1994-04-15 1997-04-29 The Regents Of The University Of California 3-hydroxy-2(1H)-pyridinone chelating agents
DE59611243D1 (de) * 1995-09-29 2005-08-11 Novartis Ag Hydroxypyridinone
GB9625638D0 (en) * 1996-12-10 1997-01-29 Cenes Ltd Therapeutic antioxidants for alzheimer's diease

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515599A (ja) * 2002-11-07 2006-06-01 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
JP4757024B2 (ja) * 2002-11-07 2011-08-24 テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド 神経保護鉄キレート剤及びそれを含む医薬組成物
US8058442B2 (en) 2002-11-07 2011-11-15 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US8685955B2 (en) 2002-11-07 2014-04-01 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
JP2013521286A (ja) * 2010-03-04 2013-06-10 メルク・シャープ・エンド・ドーム・コーポレイション カテコールｏ−メチルトランスフェラーゼの阻害剤および精神障害の治療におけるその使用
US9309199B2 (en) 2010-03-04 2016-04-12 Merck Sharp & Dohme Corp. Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
JP2021518838A (ja) * 2018-04-26 2021-08-05 嘉▲興▼▲維▼眸生物科技有限公司Ｖｉｖａｖｉｓｉｏｎ Ｂｉｏｔｅｃｈ，Ｉｎｃ． 抗炎症化合物及びその製造並びに応用
JP7364142B2 (ja) 2018-04-26 2023-10-18 イー―ニシエイト バイオファーマシューティカルズ （ハンジョウ） カンパニー リミテッド 抗炎症化合物及びその製造並びに応用

Also Published As

Publication number Publication date
GB9723078D0 (en) 1998-01-07
AU9638098A (en) 1999-05-24
WO1999023075A1 (fr) 1999-05-14
EP1027335A1 (fr) 2000-08-16

Similar Documents

Publication Publication Date Title
JP2718830B2 (ja) アニリド誘導体
JPH09507216A (ja) ５−（２−イミダゾリニルアミノ）ベンゾイミダゾール誘導体、それらの製法及びα−２−アドレノセプター作動剤としてのそれらの用途
EP1006112A1 (fr) Dérivés de 3-Hydroxy-2(1H)-pyridinone ou 3-hydroxy-4(1H)-pyridinone et utilisation en tant que capteurs d'espèces d'oxygène réaktifs (ROS)
JP2002322096A (ja) 発作および外傷性脳損傷の治療のための薬剤の組合せ
JP2002322095A (ja) 脳卒中及び外傷性脳損傷の治療のための医薬としての組み合わせ
JP2001515516A (ja) 血管損傷剤としてのコルヒノール誘導体の使用
EP1617839B1 (fr) Utilisation de derives d'azetidinecarboxamide a des fins therapeutiques
AU782816B2 (en) Optically active isomers of ketotifen and therapeutically active metabolites thereof
TW513420B (en) Chromanone and thiochromanone derivatives having steroid sulfatase inhibiting activity
PL154186B1 (en) Method for manufacturing arylic derivatives of the hydroxamic acid
US20110319482A1 (en) Novel treatments
JP2001521924A (ja) 鉄キレート化剤および酸化防止剤としてのオルト−ヒドロキシピリジノン誘導体
AU2001219180B2 (en) 5-hydroxy indazole derivatives for treating glaucoma
GB2345058A (en) Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
EP1006108A1 (fr) Dérivés de 3-hydroxy-2(1H)-pyridinone ou 3-hydroxy-4(1H)-pyridinone et utilisation comme des capteurs des espèces d'oxygène réactifs (ROS)
US20050176763A1 (en) 3-Thia-4-arylquinolin-2-one potassium channel modulators
JP3436701B2 (ja) 掻痒症の治療法
JP3034604B2 (ja) 治療用のベンズアザピン化合物
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
JPH05506012A (ja) 中枢神経系障害治療用含窒素シクロヘテロシクロアルキルアミノアリール誘導体
AU660969B2 (en) NMDA antagonists
CN1229408A (zh) 用作5－ht－2c受体拮抗剂的二氢吲哚类衍生物
JP2003505414A (ja) Ｃｎａおよび眼疾患におけるアゼチジン化合物
JPS59193873A (ja) ヘテロ環化合物
WO2001007043A1 (fr) Derives de l'azetidine carboxamine pour le traitement de troubles cerebrovasculaires

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20060110